DKK1 and plasma cell myeloma: Successful anti-myeloma treatment, including bortezomib-based regimens, immunomodulatory (IMiDS) agents or ASCT, is associated with normalization of bone remodeling that is mediated, at least in part, by reduced serum DKK1 levels26, 82.